FindTrial
Sign In

Construction and internal, external, and prospective validation study of a prediction model for extremely early recurrence after HCC resection (VERM-pre)

Construction and internal, external, and prospective validation study of a prediction model for extremely early recurrence after HCC resection (VERM-pre)

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2300077747
Enrollment
Unknown
Registered
2023-11-17
Start date
2021-12-01
Completion date
Unknown
Last updated
2023-11-21

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

hepatocellular carcinoma

Interventions

training group:none
internal validation group:none
external validaition group:none
prospective validation group:none

Sponsors

Eastern Hepatobiliary Surgery Hospital
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 80 Years

Inclusion criteria

Inclusion criteria: 1) No preoperative anticancer treatment; 2) No other known malignancies; 3) Complete data; 4) Liver function Child-Pugh A or B7 (score =7), sufficient residual liver volume calculated by liver three-dimensional reconstruction; 5) 18 years = age <85 years; 6) No extrahepatic metastasis.

Exclusion criteria

Exclusion criteria: 1)Incomplete data; 2) Patients who died within 30 days after surgery; 3) Patients who are unable to tolerate surgery; 4)Patients with concomitant other types of tumors; 5) Patients who refuse to sign informed consent.

Design outcomes

Primary

MeasureTime frame
disease-free survival;—

Secondary

MeasureTime frame
overall survival time;—

Countries

China

Contacts

Public ContactWeiping Zhou

Eastern Hepatobiliary Surgery Hospital

ehphwp@126.com+86 136 0161 6763

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026